Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Growth Hormone Deficiency Market from 2024 to 2025?
Over the past few years, the market size for growth hormone deficiency has seen strong expansion. The market which is currently valued at $4.06 billion in 2024 is projected to expand to $4.31 billion in 2025, with a compound annual growth rate (CAGR) of 6.1%. Factors such as the surge in strategic initiatives, increasing occurrences of brain tumors, escalating demand for hormone therapy, growth in the geriatric population, and enhanced government health care funding have fueled the growth experienced in the historic period.
What Is the Projected Market Size of the Growth Hormone Deficiency Market?
The market for growth hormone deficiency is predicted to witness profound expansion in the forthcoming years, with an anticipated increase to $5.42 billion by 2029, demonstrating an annual compound growth rate of 5.9%. This predicted expansion during the forecast period can be credited to the escalating incidence of genetic abnormalities, an increasing volume of strategic initiatives, intensification of research and development efforts, growing Gh disease morbidity, and an escalated count of clinical examinations. The forecast period is also anticipated to see essential trends like technological advancements, broadened treatment alternatives, progressive diagnostic methods, innovation and recent progress, and strides in biotechnology.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21197&type=smp
Who are the Major Competitors in the Growth Hormone Deficiency Market Outlook?
Major companies operating in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.
What Is Fueling Growth in the Growth Hormone Deficiency Market?
The increase in genetic disorders is projected to spur the advancement of the market for growth hormone deficiency. Genetic disorders are medical conditions caused by DNA abnormalities or mutations, either inherited or spontaneous. The rise in these disorders is attributed to improved diagnostic technology, heightened awareness, increasing maternal age, environmental factors triggering mutations, population growth, and better survival rates for those affected. Growth hormone deficiency is employed to manage growth-related complications in certain genetic conditions. For example, a report from the Department of Health & Social Care (DHSC), a UK governmental department, stated that in October 2022, around 33,000 whole genome equivalents were sequenced. The average diagnostic yield was 32%, escalating to 61% in certain conditions, according to the report published in December 2022. Consequently, the escalating prevalence of genetic disorders fuels the advancement of the growth hormone deficiency market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21197&type=smp
Which Growth Hormone Deficiency Market Segments Are Growing the Fastest?
The growth hormone deficiency market covered in this report is segmented –
1) By Type: Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency
2) By Treatment: Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, Surgery
3) By Route Of Administration: Intravenous, Intramuscular, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency, Genetic Growth Hormone Deficiency, Acquired Growth Hormone Deficiency
2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency, Secondary Growth Hormone Deficiency
Which Industry Trends Are Shaping the Future of the Growth Hormone Deficiency Market?
Leading firms in the growth hormone deficiency market are channeling their efforts into creating revolutionary products such as unmodified somatropin for everyday pediatric growth hormone deficiency treatments. Unmodified somatropin is the same growth hormone used daily for these treatments but handled in an innovative way: a once-weekly dosage delivered via Skytrofa. Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, made a bold move in this direction by launching SKYTROFA (lonapegsomatropin) in September 2023. This groundbreaking treatment, the first and only of its kind approved by the FDA for once-weekly administration, elevates convenience, enhances patient adherence, and potentially outperforms traditional everyday growth hormone treatments. It is poised as a landmark achievement in the fields of endocrinology and pediatric care.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/growth-hormone-deficiency-global-market-report
Which Countries Are Leading the Growth Hormone Deficiency Market?
North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21197
This Report Delivers Insight On:
1. How big is the growth hormone deficiency market, and how is it changing globally?
2. Who are the major companies in the growth hormone deficiency market, and how are they performing?
3. What are the key opportunities and risks in the growth hormone deficiency market right now?
4. Which products or customer segments are growing the most in the growth hormone deficiency market?
5. What factors are helping or slowing down the growth of the growth hormone deficiency market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model